Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells

Nucleic Acids Research
Taavi LehtoPrisca Boisguerin

Abstract

Cell-penetrating peptide-mediated delivery of phosphorodiamidate morpholino oligomers (PMOs) has shown great promise for exon-skipping therapy of Duchenne Muscular Dystrophy (DMD). Pip6a-PMO, a recently developed conjugate, is particularly efficient in a murine DMD model, although mechanisms responsible for its increased biological activity have not been studied. Here, we evaluate the cellular trafficking and the biological activity of Pip6a-PMO in skeletal muscle cells and primary cardiomyocytes. Our results indicate that Pip6a-PMO is taken up in the skeletal muscle cells by an energy- and caveolae-mediated endocytosis. Interestingly, its cellular distribution is different in undifferentiated and differentiated skeletal muscle cells (vesicular versus nuclear). Likewise, Pip6a-PMO mainly accumulates in cytoplasmic vesicles in primary cardiomyocytes, in which clathrin-mediated endocytosis seems to be the pre-dominant uptake pathway. These differences in cellular trafficking correspond well with the exon-skipping data, with higher activity in myotubes than in myoblasts or cardiomyocytes. These differences in cellular trafficking thus provide a possible mechanistic explanation for the variations in exon-skipping activity and resto...Continue Reading

References

Sep 11, 2002·Neuromuscular Disorders : NMD·G DicksonI R Graham
Aug 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mattie Bremmer-BoutJudith C T van Deutekom
Sep 4, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Stéphanie Barrère-LemaireChristophe Piot
Dec 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Qi Long LuTerence Partridge
Sep 15, 2006·Nature Reviews. Molecular Cell Biology·Kay E Davies, Kristen J Nowak
Jun 23, 2007·Nucleic Acids Research·Saïd AbesBernard Lebleu
Dec 28, 2007·The New England Journal of Medicine·Judith C van DeutekomGert-Jan B van Ommen
Jun 12, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Natee JearawiriyapaisarnRyszard Kole
Sep 23, 2008·Proceedings of the National Academy of Sciences of the United States of America·Bo WuQi Long Lu
Mar 17, 2009·Annals of Neurology·Toshifumi YokotaEric Hoffman
Oct 22, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Aurélie GoyenvalleKay E Davies
Nov 10, 2009·Cellular and Molecular Life Sciences : CMLS·F Said HassaneBernard Lebleu
Nov 26, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alberto MalerbaGeorge Dickson
Mar 25, 2011·The New England Journal of Medicine·Nathalie M GoemansJudith C van Deutekom
Apr 21, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·HaiFang YinMatthew Ja Wood
Apr 27, 2012·Current Gene Therapy·Samir A El AndaloussiMatthew J A Wood
May 19, 2012·Expert Opinion on Drug Delivery·Taavi LehtoÜlo Langel
Jun 1, 2012·Human Gene Therapy·Helen FosterGeorge Dickson
Aug 16, 2012·Current Opinion in Neurology·Ingrid E C Verhaart, Annemieke Aartsma-Rus
Nov 13, 2012·Current Pharmaceutical Design·Corinne A Betts, Matthew J A Wood
Apr 24, 2013·Nature Reviews. Genetics·Rebecca J FaircloughKay E Davies

❮ Previous
Next ❯

Citations

Dec 11, 2014·Therapeutic Delivery·Janely Pae, Margus Pooga
Apr 18, 2015·Advanced Drug Delivery Reviews·R L Juliano, K Carver
Mar 10, 2015·Advanced Drug Delivery Reviews·Prisca BoisguérinBernard Lebleu
Jun 9, 2015·Trends in Molecular Medicine·S D WiltonS Fletcher
Apr 17, 2016·Nucleic Acids Research·Rudolph L Juliano
Dec 24, 2014·Nanomedicine·Taavi Lehto, Ernst Wagner
Nov 28, 2014·Biomolecular Concepts·Carmine Pasquale CerratoÜlo Langel
Jun 9, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Egon UrgardAna Rebane
Sep 28, 2016·Intractable & Rare Diseases Research·Bo BaoToshifumi Yokota
Aug 16, 2016·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Matt GoodingCaitriona M O'Driscoll
Apr 12, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Michael E NanceDongsheng Duan
Dec 15, 2017·Nucleic Acids Research·Xiulong Shen, David R Corey
May 8, 2018·Biomedicines·Graham McClorey, Subhashis Banerjee
Jun 5, 2018·Expert Opinion on Therapeutic Targets·James S NovakTerence A Partridge
Oct 5, 2018·Annual Review of Pharmacology and Toxicology·C I Edvard Smith, Rula Zain
Jun 11, 2019·Human Molecular Genetics·Ngoc Lu-NguyenAlberto Malerba
Mar 16, 2017·EMBO Molecular Medicine·Caroline GodfreyVirginia Arechavala-Gomeza
Oct 1, 2019·The Journal of Clinical Investigation·Elizabeth M McNally, Brian D Leverson
Jun 27, 2018·Biomedicines·James T MarchLinda J Popplewell
Nov 28, 2018·Journal of Personalized Medicine·Kenji Rowel Q LimToshifumi Yokota
Aug 13, 2020·Nature Reviews. Drug Discovery·Thomas C RobertsMatthew J A Wood
Oct 20, 2020·Expert Opinion on Biological Therapy·Anne-Fleur E Schneider, Annemieke Aartsma-Rus
Jan 7, 2021·Expert Opinion on Biological Therapy·Tejal AsleshToshifumi Yokota
Feb 15, 2019·Molecular Therapy. Nucleic Acids·Shouta MiyatakeYoshitsugu Aoki
Nov 20, 2021·Archives of Toxicology·Omar Sheikh, Toshifumi Yokota
Nov 7, 2021·The Journal of Allergy and Clinical Immunology·Anne MarchalotLaurent Delpy

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
fluorescence spectroscopy
transfections
transfection
FACS
fluorescence
fluorescence microscopy

Software Mentioned

Axio Vision
Prism
GraphPad Prism GraphPad

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.